NeuroMetrix (NASDAQ:NURO) Stock Passes Above 200 Day Moving Average – Should You Sell?

NeuroMetrix, Inc. (NASDAQ:NURO)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $4.11 and traded as high as $4.39. NeuroMetrix shares last traded at $4.42, with a volume of 1,085 shares.

Analyst Ratings Changes

Separately, StockNews.com began coverage on NeuroMetrix in a report on Thursday. They issued a “sell” rating for the company.

NeuroMetrix Price Performance

The stock has a market cap of $9.26 million, a P/E ratio of -0.98 and a beta of 2.15. The company has a fifty day moving average price of $4.29 and a 200 day moving average price of $4.11.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC bought a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix as of its most recent SEC filing. Hedge funds and other institutional investors own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.